Medicenna Therapeutics received patent approval from the United States Patent and Trademark Office for related to the company’s lead candidate MDNA55.
Medicenna Therapeutics (TSXV:MDNA) received patent approval from the United States Patent and Trademark Office for related to the company’s lead candidate MDNA55. The patent also covers the combination of MDNA55 with other anti-cancer therapeutic agents.
As quoted in the press release:
“Medicenna continues to progress with the Phase 2b clinical trial of MDNA55 as a single agent, targeted immunotherapeutic for the treatment of recurrent glioblastoma, a uniformly fatal form of brain cancer,” said Dr. Fahar Merchant, Chairman, President and CEO of Medicenna. “Given the unique dual-targeted mechanism of MDNA55, and its synergistic effect when combined with other therapeutics, the issued patent will allow us to further improve patient outcomes and establish drug development partnerships for new cancer indications.”
Medicenna continues to strategically expand its Superkine and Empowered Cytokine platforms which comprises over 40 filed or issued patents in key territories including US, Canada, EU and Asia.